1. In Vivo

Bayer Diagnostics Gets Rolling

Bayer AG's purchase of Chiron Diagnostics for $1.1 billion in cash demonstrates its commitment to diagnostics and also indicates Chiron Corp.'s negotiating savvy. Bayer is buying Chiron Diagnostics in order to get access to its immunoassay, critical care and nucleic acid probe businesses, as well as additional sales and marketing support to help it roll out a plethora of new products in the next year. Chiron is getting out of diagnostics in order to concentrate on pharmaceuticals and doesn't yet know how it will use the money. But Chiron is retaining rights to HCV and to the blood screening business and expects the deal in its entirety to generate $2 billion for it over the next few years.

If Bayer AG 's willingness to pay $1.1 billion in cash for Chiron Diagnostics Corp.[See Deal] demonstrates its commitment to the field, the deal also indicates Chiron Corp. 's negotiating savvy. In the barest details, Bayer gets Chiron's blood-gas analyzer business, its immunoassay business, and its nucleic acid probe technologies. Moreover, it gets non-exclusive rights to some key Chiron patents for HCV and HIV testing. Bayer AG's overall ranking in life sciences moves up a notch or two, bolstering its position as an integrated health care company, while its diagnostics subsidiary jumps from being sixth in size to fourth, with sales of more than $1.8 billion.

While the deal helps Bayer Diagnostics Inc. round out its product portfolio and gain market clout, Chiron certainly is the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By David Wild

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

More from In Vivo

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By David Wild

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

BioBytes: AI-Related Deals In Q2 ‘25

 
• By David Wild

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 
• By Eleanor Malone, Edwin Elmhirst, and Kosh Naran

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.